-
Je něco špatně v tomto záznamu ?
Apolipoprotein E ?4-positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: A 15-year disease history model based on a 4-year longitudinal study
Horáková D, Kýr M, Havrdová E, Doležal O, Lelková P, Pospíšilová L, Bergsland N, Dwyer MG, Cox JL, Hussein S, Seidl Z, Vaněčková M, Krásenský J, Zivadinov R.
Jazyk angličtina Země Česko
Grantová podpora
1A8713
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Část
Zdroj
NLK
Free Medical Journals
od 2000
Freely Accessible Science Journals
od 2000
ProQuest Central
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
- MeSH
- adjuvancia imunologická terapeutické užití MeSH
- antiflogistika terapeutické užití MeSH
- apolipoprotein E4 genetika imunologie MeSH
- atrofie patologie MeSH
- azathioprin terapeutické užití MeSH
- dospělí MeSH
- financování organizované MeSH
- genotyp MeSH
- imunosupresiva terapeutické užití MeSH
- interferon beta terapeutické užití MeSH
- kombinovaná farmakoterapie MeSH
- lidé MeSH
- longitudinální studie MeSH
- magnetická rezonanční tomografie MeSH
- mozek patologie MeSH
- následné studie MeSH
- nervová vlákna myelinizovaná patologie MeSH
- počítačové zpracování obrazu MeSH
- prednison terapeutické užití MeSH
- progrese nemoci MeSH
- relabující-remitující roztroušená skleróza farmakoterapie genetika patologie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
Multiple sclerosis is a disease with considerable individual variation, and genetic background plays a key role in disease susceptibility and severity. The objective of the study was to evaluate the relationship between apolipoprotein E (APOE) genotype and the evolution of different clinical and MRI parameters. We investigated a group of 150 relapsingremitting patients that completed 4-year follow-up. The mean age was 30.2 years, disease duration 56.8 months, and baseline Expanded Disability Status Scale (EDSS) 1.8. The changes in brain parenchymal volume (BPV), gray matter (GMV), white matter (WMV) and peripheral gray volume (PGMV) were measured by SIENA/X. T2-lesion volume was assessed by semi-automated methods. The mixed-effect model analysis was used to investigate evolution of clinical and MRI parameters in relation to the APOE ?4 genotype considering two different time models: 4-year follow-up and 15-year period from disease onset. We identified 36 APOE ?4-positive patients. Decline of GMV (P = 0.017), and BPV (P = 0.029) were significantly faster in APOE ?4-positive than in APOE ?4-negative patients in the 15-year model. In the 4- year model, a trend for faster decrease of GMV was found in APOE ?4-positive patients (P = 0.067). No differences in other MRI parameters or EDSS were found between the APOE groups. The results of the study suggest that APOE ?4-positive patients experience faster rate of gray matter atrophy.
Lit.: 47
- 000
- 00000naa 2200000 a 4500
- 001
- bmc11006056
- 003
- CZ-PrNML
- 005
- 20140325144347.0
- 008
- 110330s2010 xr e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Horáková, Dana $7 xx0076527
- 245 10
- $a Apolipoprotein E ?4-positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: A 15-year disease history model based on a 4-year longitudinal study / $c Horáková D, Kýr M, Havrdová E, Doležal O, Lelková P, Pospíšilová L, Bergsland N, Dwyer MG, Cox JL, Hussein S, Seidl Z, Vaněčková M, Krásenský J, Zivadinov R.
- 314 __
- $a Charles University in Prague, First Faculty of Medicine, Department of Neurology and Center of Clinical Neuroscience, Prague
- 504 __
- $a Lit.: 47
- 520 9_
- $a Multiple sclerosis is a disease with considerable individual variation, and genetic background plays a key role in disease susceptibility and severity. The objective of the study was to evaluate the relationship between apolipoprotein E (APOE) genotype and the evolution of different clinical and MRI parameters. We investigated a group of 150 relapsingremitting patients that completed 4-year follow-up. The mean age was 30.2 years, disease duration 56.8 months, and baseline Expanded Disability Status Scale (EDSS) 1.8. The changes in brain parenchymal volume (BPV), gray matter (GMV), white matter (WMV) and peripheral gray volume (PGMV) were measured by SIENA/X. T2-lesion volume was assessed by semi-automated methods. The mixed-effect model analysis was used to investigate evolution of clinical and MRI parameters in relation to the APOE ?4 genotype considering two different time models: 4-year follow-up and 15-year period from disease onset. We identified 36 APOE ?4-positive patients. Decline of GMV (P = 0.017), and BPV (P = 0.029) were significantly faster in APOE ?4-positive than in APOE ?4-negative patients in the 15-year model. In the 4- year model, a trend for faster decrease of GMV was found in APOE ?4-positive patients (P = 0.067). No differences in other MRI parameters or EDSS were found between the APOE groups. The results of the study suggest that APOE ?4-positive patients experience faster rate of gray matter atrophy.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a adjuvancia imunologická $x terapeutické užití $7 D000276
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antiflogistika $x terapeutické užití $7 D000893
- 650 _2
- $a apolipoprotein E4 $x genetika $x imunologie $7 D053327
- 650 _2
- $a atrofie $x patologie $7 D001284
- 650 _2
- $a azathioprin $x terapeutické užití $7 D001379
- 650 _2
- $a mozek $x patologie $7 D001921
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a genotyp $7 D005838
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a počítačové zpracování obrazu $7 D007091
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a interferon beta $x terapeutické užití $7 D016899
- 650 _2
- $a longitudinální studie $7 D008137
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $x genetika $x patologie $7 D020529
- 650 _2
- $a nervová vlákna myelinizovaná $x patologie $7 D009413
- 650 _2
- $a prednison $x terapeutické užití $7 D011241
- 700 1_
- $a Kýr, Michal. $7 mub2014808498
- 700 1_
- $a Kubala Havrdová, Eva, $d 1955- $7 nlk19990073204
- 700 1_
- $a Doležal, Ondřej, $d 1979- $7 xx0075512
- 700 1_
- $a Lelková, Petra $7 xx0142909
- 700 1_
- $a Pospíšilová, Lenka $7 xx0142906
- 700 1_
- $a Bergsland, N.
- 700 1_
- $a Dwyer, M. G.
- 700 1_
- $a Cox, J. L.
- 700 1_
- $a Hussein, S.
- 700 1_
- $a Seidl, Zdeněk, $d 1950- $7 mzk2004258727
- 700 1_
- $a Vaněčková, Manuela, $d 1973- $7 mzk2007377403
- 700 1_
- $a Krásenský, Jan $7 xx0096156
- 700 1_
- $a Zivadinov, R.
- 773 0_
- $w MED00011004 $t Folia biologica $g Roč. 56, č. 6 (2010), s. 242-251 $x 0015-5500
- 856 41
- $u https://fb.cuni.cz/Data/files/folia_biologica/volume_56_2010_6/fb2010A0033.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 970 $c 89 $y 2 $z 0
- 990 __
- $a 20110330145758 $b ABA008
- 991 __
- $a 20140325144421 $b ABA008
- 999 __
- $a ok $b bmc $g 833564 $s 698145
- BAS __
- $a 3
- BMC __
- $a 2010 $b 56 $c 6 $d 242-251 $m Folia biologica (Praha) $x MED00011004
- GRA __
- $a 1A8713 $p MZ0
- LZP __
- $a 2011-05/mkme